EDX Medical Group PLC General Meeting results (2978R)
25 Octubre 2023 - 9:00AM
UK Regulatory
TIDMEDX
RNS Number : 2978R
EDX Medical Group PLC
25 October 2023
EDX Medical Group plc
General Meeting
October 25, 2023
Result of General Meeting
The General Meeting of EDX Medical Group plc was held at the
Roosevelt Room, Brown's Hotel, Albemarle Street, London, on 25
October 2023 at 2:00 p.m.
All three resolutions put to members were passed on a poll as
ordinary resolutions.
The number of votes cast for and against each of the resolutions
proposed, and the number of votes withheld were as follows:
Resolution Votes for % Votes against % Votes withheld
Resolution 1 ( Ordinary
)
To receive the Annual Report
and Accounts of the Company
for the financial year
ended 31 March 2023 together
with the Directors' reports
and auditor's report on
those accounts. 149,949,300 100.00 0 0.00 0
------------ ------- -------------- ----- ---------------
Resolution 2 ( Ordinary
)
To re-appoint PKF Littlejohn
LLP as auditor of the Company
to hold office until the
conclusion of the next
general meeting at which
accounts are laid before
the Company. 149,949,300 100.00 0 0.00 0
------------ ------- -------------- ----- ---------------
Resolution 3 ( Ordinary
)
To authorise the Directors
to determine the fees payable
to the auditor. 149,949,300 100.00 0 0.00 0
------------ ------- -------------- ----- ---------------
As at 25 October 2023, there were 300,965,909 ordinary shares in
issue. Shareholders are entitled to one vote per share. Votes
withheld are not votes in law and so have not been included in the
calculation of the proportion of votes for and against a
resolution.
The full text of each resolution is available in the Notice of
General Meeting, published on our website.
About EDX Medical Group
EDX Medical Group plc develops innovative digital diagnostic
products and services, enabling cost effective and timely delivery
of personalised treatment for cancer, heart disease and infectious
diseases. The company is listed on the AQSE Growth Market (TIDM:
EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE,
a medical and life sciences entrepreneur with more than 30 years of
experience, together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions
combining advanced biological and digital technologies, EDX Medical
seeks to cost-effectively improve the detection and
characterisation of disease in order to personalise treatment in a
timely fashion. Early disease detection and biologically-based
personal treatment optimisation is considered to be the most
impactful way of reducing deaths and lowering the cost of
healthcare globally.
EDX Medical has established expertise in the design,
development, validation and sourcing of diagnostic testing
solutions to ISO 13485 and key laboratory tests performed by the
Company have been accredited to ISO 15189 by the United Kingdom
Accreditation Service (UKAS).
EDX Medical Group operates a molecular biology and diagnostics
laboratory in Cambridge, UK, and 100%-owned subsidiary companies,
Hutano Diagnostics Limited in Oxford, UK, and Torax Biosciences Ltd
in Ireland.
Learn more: www.edxmedical.co.uk.
Contacts:
EDX Medical plc
Dr Mike Hudson (Chief Executive
Officer) +44 (0)7812 345 301
Oberon Capital
Nick Lovering (Corporate Adviser)
Adam Pollock (Corporate Broking)
Mike Seabrook (Corporate Broking) +44 (0)20 3179 5300
Media House International
Ramsay Smith +44 (0)7788 414856
ramsay@mediahouse.co.uk
Gary McQueen + 44 (0)7834 694609
gary@mediahouse.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXMABJTMTITBLJ
(END) Dow Jones Newswires
October 25, 2023 10:00 ET (14:00 GMT)
EDX Medical (AQSE:EDX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
EDX Medical (AQSE:EDX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024